CN Patent

CN113316458B — 抗lag3抗体和抗pd-1抗体的共制剂

Assigned to Merck Sharp and Dohme BV · Expires 2024-08-02 · 2y expired

What this patent protects

本发明提供了抗PD‑1抗体和抗LAG3抗体的共制剂，及其在治疗各种病症中的用途。

USPTO Abstract

本发明提供了抗PD‑1抗体和抗LAG3抗体的共制剂，及其在治疗各种病症中的用途。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN113316458B
Jurisdiction: CN
Classification: —
Expires: 2024-08-02
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme BV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.